Article in Science advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
21 authors at 7 institutions in 2 countries.
Manabu AokiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-7089-831X
Hiromi Aoki-OgataExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-9290-911X
Haydar BulutExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0003-0262-6296
Hironori HayashiDepartment of Intelligent Network for Infection Control, Tohoku University Graduate School of Medicine, Miyagi, Japan.ORCID 0000-0002-5892-0040
Nobutoki TakamuneDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0001-7173-240X
Naoki KishimotoDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-9401-8118
Hiroki TanakaDepartment of Structural Virology, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Nobuyo Higashi-KuwataDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0002-9404-3532
Shin-Ichiro HattoriDepartment of Refractory Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0002-5637-3397
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9943-5888
Kalapala Venkateswara RaoDepartments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, IN, USA.
Kazuya IwamaDepartment of Intelligent Network for Infection Control, Tohoku University Graduate School of Medicine, Miyagi, Japan.
David A DavisViral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Kazuya HasegawaStructural Biology Division, Japan Synchrotron Radiation Research Institute, Hyogo, Japan.ORCID 0000-0003-0331-1624
Kazutaka MurayamaDivision of Biomedical Measurements and Diagnostics, Graduate School of Biomedical Engineering, Tohoku University, Miyagi, Japan.
Robert YarchoanViral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-3057-1395
Arun K GhoshDepartments of Chemistry and Medicinal Chemistry, Purdue University, West Lafayette, IN, USA.
Alice K PauNational Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-0153-0236
Shinichi MachidaDepartment of Structural Virology, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Shogo MisumiDepartment of Environmental and Molecular Health Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.ORCID 0000-0002-9465-4720
Hiroaki MitsuyaExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0001-9274-3853
National Institutes of Health · USNational Center for Global Health and Medicine · JPKumamoto Health Science University · JPPurdue University West Lafayette · USTohoku Institute of Technology · JPJapan Synchrotron Radiation Research Institute · JPTohoku University · JP
Funding
Development of Antiviral Therapy of HIV-1 InfectionZIASC006738 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI MITSUYA, HIROAKI · 2009 to 2025
$10.0M
Design & Synthesis of Nonpeptide Protease InhibitorsR01AI150466 · NIAID · PURDUE UNIVERSITY · PI ARUN K GHOSH · 2023 to 2026
$2.4M
Design & Synthesis of Nonpeptide Protease InhibitorsR37AI150466 · NIAID · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2019 to 2020
Nuclear localization signal (NLS) of HIV-1 integrase (IN) is implicated in nuclear import of HIV-1 preintegration complex (PIC). Here, we established a multiclass drug-resistant HIV-1 variant (HIV
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants. · full record | OpenQuestion